Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Cediranib (AZD2171)
Cat No.
CEI-0040
Description
Cediranib (AZD2171) can inhibit VEGFR2, FLT-1 and FLT-4 with IC50 of 0.5 nM, 5 nM and 3 nM.
Alias
Recentin
CAS No.
288383-20-0
Molecular Weight
450.51
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
Recentin
Targets
VEGFR2, FLT-1, FLT-4
Molecular Formula
C25H27FN4O3
Chemical Name
4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
Solubility
DMSO 90 mg/mL Water
In vitro
AZD2171 is a novel indole-ether quinazoline inhibitor. AZD2171, as an ATP-competitive inhibitor, can potently inhibit KDR tyrosine kinase with IC50 less than 1 nM in vitro. AZD2171 are consistent with potent inhibition of VEGF signaling, angiogenesis, neovascular survival, and tumor growth.In human umbilical vein endothelial cells, AZD2171 inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 nM and 0.5 nM, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, AZD2171 also reduced vessel area, length, and branching at subnanomolar concentrations.
Download
Download Datasheet